Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Cuprina Holdings Cayman Limited's Competitiveness

Name: Cuprina Holdings Cayman Limited Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Cuprina Holdings Cayman Limited (CUPR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

Competitors Tracked

Publicly traded peers

Peer Group Market Share

100.00 %

vs 100.00 % a year ago

Revenue Growth Y/Y

9.20 %

Q4 2025

Net Margin

-9,366.70 %

Q4 2025

Key Findings: Cuprina Holdings Cayman Limited vs Its Competitors

TTM: Trailing 12-month revenue of 0M vs -M combined for tracked competitors (100.0% combined share).
Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Scale: Cuprina Holdings Cayman Limited ranks #182 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
Peer revenue share: Cuprina Holdings Cayman Limited accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

CUPR Sales vs. its Competitors, Q4 2025

Cuprina Holdings Cayman Limited generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/CUPR/competitors                    

                        https://api.csimarket.com/api/v1/companies/CUPR/relationships                    

                        https://api.csimarket.com/api/v1/companies/CUPR/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 9.2% for Cuprina Holdings Cayman Limited. Cuprina Holdings Cayman Limited's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Cuprina Holdings Cayman Limited's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Cuprina Holdings cayman Limited	-	Yes	No	Yes
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

CUPR Stock Performance relative to its Competitors

CUPR Competitors (weighted) Percent change over the selected range

Cuprina Holdings Cayman Limited's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(1 of 7)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Cuprina Holdings cayman Limited	-79.10 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (7)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Cuprina Holdings Cayman Limited's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

CUPR Stock Performance relative to Similar-Size Competitors

CUPR Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Cuprina Holdings Cayman Limited's Comment on Competition and Industry Peers

The company’s product portfolio includes bioactives with properties that enhance performance compared to conventional treatments, supported by clinical and health economic outcomes data. Its current offerings include maggot-based chronic wound care products designed to disinfect wounds and promote healing in patients unresponsive to standard treatments. Pipeline products under development include medical grade leeches for hirudotherapy and bullfrog sponge dressings intended to compete with other animal-derived collagen wound care dressings in Singapore. The bullfrog sponge dressings are planned for markets such as the United States, Singapore, Hong Kong, mainland China, Saudi Arabia, and ASEAN countries, subject to research, development, and regulatory approvals. The company is also researching additional bullfrog collagen-based products. Prior to development, it conducts comprehensive assessments of feasibility, clinical need, patient population, potential competitors, regulatory requirements, and associated risks for new medical devices.

Cuprina Holdings Cayman Limited's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).

Company	Largest Segment	2nd Segment	3rd Segment
Cuprina Holdings cayman Limited	Cosmeceutical Product 14.67 %	-	-

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).